In this episode, Drs. Erin Michos and Christie Ballantyne examine the importance of testing and identifying lipoprotein(a) (Lp[a]) levels in patients, research highlighting trends in populations at risk, and the genetic factors involved in assessment. The significance associated with various levels of Lp(a) in measurement and how testing plays a role in management are also discussed.

This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!

Related References:

1. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;Mar 29:[ePub ahead of print].